ANAB - Why Is Skin Disease Focused AnaptysBio Stock Trading Higher Today? | Benzinga
AnaptysBio Inc (NASDAQ: ANAB) released topline results from its global Phase 3 GEMINI-1 trial of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares.
During a GPP flare, individuals experience the sudden eruption of painful pustules. These pustules appear over large areas of the skin, accompanied by redness, severe itchiness, and dry, cracked, or scaly skin.
Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of ...